These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 24813310)
1. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review. Peng ZF; Yang L; Wang TT; Han P; Liu ZH; Wei Q J Urol; 2014 Nov; 192(5):1424-30. PubMed ID: 24813310 [TBL] [Abstract][Full Text] [Related]
2. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959 [TBL] [Abstract][Full Text] [Related]
3. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Davies DM; de Vries PJ; Johnson SR; McCartney DL; Cox JA; Serra AL; Watson PC; Howe CJ; Doyle T; Pointon K; Cross JJ; Tattersfield AE; Kingswood JC; Sampson JR Clin Cancer Res; 2011 Jun; 17(12):4071-81. PubMed ID: 21525172 [TBL] [Abstract][Full Text] [Related]
4. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Whittemore VH; Chen D; Sahmoud T; Shah G; Lincy J; Lebwohl D; Budde K Lancet; 2013 Mar; 381(9869):817-24. PubMed ID: 23312829 [TBL] [Abstract][Full Text] [Related]
5. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Wienecke R; Fackler I; Linsenmaier U; Mayer K; Licht T; Kretzler M Am J Kidney Dis; 2006 Sep; 48(3):e27-9. PubMed ID: 16931204 [TBL] [Abstract][Full Text] [Related]
6. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. Budde K; Zonnenberg BA; Frost M; Cheung W; Urva S; Brechenmacher T; Stein K; Chen D; Kingswood JC; Bissler JJ Br J Clin Pharmacol; 2016 May; 81(5):958-70. PubMed ID: 26580489 [TBL] [Abstract][Full Text] [Related]
8. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures. Watanabe EH; Coelho FMA; Filho HL; Balbo BEP; Neves PDMM; Franzin FM; Yamauchi FI; Onuchic LF Sci Rep; 2021 Apr; 11(1):8493. PubMed ID: 33875750 [TBL] [Abstract][Full Text] [Related]
9. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Belousova E; Frost MD; Sauter M; Brakemeier S; de Vries PJ; Berkowitz N; Voi M; Peyrard S; Budde K PLoS One; 2017; 12(8):e0180939. PubMed ID: 28792952 [TBL] [Abstract][Full Text] [Related]
10. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. Davies DM; Johnson SR; Tattersfield AE; Kingswood JC; Cox JA; McCartney DL; Doyle T; Elmslie F; Saggar A; de Vries PJ; Sampson JR N Engl J Med; 2008 Jan; 358(2):200-3. PubMed ID: 18184971 [No Abstract] [Full Text] [Related]
11. Bilateral renal angiomyolipoma coexistent with pulmonary lymphangioleiomyomatosis and tuberous sclerosis. Yoshida S; Hayashi T; Ishii N; Yoshinaga A; Ohno R; Terao T; Watanabe T; Yamada T; Osada H Int Urol Nephrol; 2006; 38(3-4):413-5. PubMed ID: 17111084 [TBL] [Abstract][Full Text] [Related]
12. Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease. Torun D; Micozkadioglu H; Gedikoglu M; Ozelsancak R; Tekkarismaz N Saudi J Kidney Dis Transpl; 2019; 30(2):545-548. PubMed ID: 31031395 [TBL] [Abstract][Full Text] [Related]
13. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809 [TBL] [Abstract][Full Text] [Related]
15. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex. Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282 [TBL] [Abstract][Full Text] [Related]
16. Sirolimus can promote the disappearance of renal angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study. Dun S; Wang YY; Wan L; Wang QH; Lu Q; Yang XY; Zhang Q; Chen HM; Qiu LP; Zou LP World J Pediatr; 2024 Jun; 20(6):602-610. PubMed ID: 37773307 [TBL] [Abstract][Full Text] [Related]
17. Conservative management of pulmonary lymphangioleiomyomatosis and tuberous sclerosis complicated by renal angiomyolipomas in pregnancy. Cleary-Goldman J; Sanghvi AV; Nakhuda GS; Robinson JN J Matern Fetal Neonatal Med; 2004 Feb; 15(2):132-4. PubMed ID: 15209123 [TBL] [Abstract][Full Text] [Related]
18. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041 [TBL] [Abstract][Full Text] [Related]
19. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. Bissler JJ; Nonomura N; Budde K; Zonnenberg BA; Fischereder M; Voi M; Louveau AL; Herbst F; Bebin EM; Curatolo P; Zonta A; Belousova E PLoS One; 2018; 13(9):e0201005. PubMed ID: 30192751 [TBL] [Abstract][Full Text] [Related]
20. [Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex]. Dun S; Zou LP; Zhang MN; Wang YY; He W; Chen HM; Hu LY; Chen XQ; Lu Q; Pang LY; Liu LY; Tang LN; Wang B Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):852-856. PubMed ID: 31665839 [No Abstract] [Full Text] [Related] [Next] [New Search]